SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. Despite bullish longer-term moving averages and notable insider buying, near-term momentum is weakening (MACD histogram negative and expanding) and the latest quarter (2025/Q3) shows clear fundamental deterioration (revenue down 22% YoY, margins down, turning to a larger loss). With no Intellectia buy signals today and a modestly negative 1-month statistical drift (-2.5%), I would avoid initiating a new position at $5.155 and only consider entry after a clean break/hold above ~$5.29 (R1) or on a pullback closer to ~$5.02 (pivot) with improving momentum.
Trend/momentum is mixed. Structure is bullish (SMA_5 > SMA_20 > SMA_200), implying the broader trend is up, but short-term momentum is fading: MACD histogram is below zero (-0.00387) and negatively expanding, which often precedes near-term weakness or consolidation. RSI(6) at ~58.9 is neutral-to-slightly bullish, not an overbought condition. Key levels: pivot support ~5.018 (near current price), resistance at R1 ~5.293 then R2 ~5.463; support levels at S1 ~4.743 and S2 ~4.573. Near-term pattern odds provided suggest -0.3% next day, +0.39% next week, and -2.5% next month, consistent with choppy-to-slightly down near-term action.
Intellectia Proprietary Trading Signals
Heavy insider buying trend (buying amount up ~4279% over the last month) is a notable confidence signal.
Technical structure remains bullish via moving averages, so a breakout above ~$5.29 could trigger momentum buyers.
Earnings upcoming: QDEC 2025 report on 2026-02-11 after hours could act as a catalyst if results/guide surprise positively.
Weak latest quarter fundamentals (2025/Q3): revenue -22.12% YoY, net income -177.61% YoY to a larger loss, EPS -0.06, and gross margin down sharply—this is the main overhang.
Momentum deterioration (MACD negative and worsening) increases odds of a near-term pullback from current levels.
Very high implied volatility (IV percentile ~92.
suggests the market expects instability; it can also precede post-event volatility crush and choppy price action.
No supportive news flow in the past week, reducing near-term narrative catalysts.
Latest reported quarter: 2025/Q3. Growth trends are negative: revenue fell to $6.884M (-22.12% YoY). Profitability deteriorated materially: net income declined to -$0.943M (-177.61% YoY), EPS -0.06 (-185.71% YoY). Gross margin dropped to 39.41% (-33.52% YoY). Overall, the quarter indicates contracting sales and pressure on margins/profitability rather than an improving growth trajectory.
No analyst rating or price target change data was provided, so a current Wall Street consensus trend cannot be confirmed from the dataset. Pros (typical bull view, based on available info): insider buying and a small-cap setup that could re-rate on an earnings turn. Cons (typical bear view, based on available info): shrinking revenue, worsening losses, and margin compression—fundamentals currently do not justify chasing the stock without clear evidence of an operational inflection.
